Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy
Largest study of its kind provides new insights on lymphoma biology to guide clinical approaches
Researchers identified three subgroups with differential benefit from CD19 CAR T cell therapy
Study points to opportunities for alternative approaches to treat patients who do not benefit from CAR T cell therapies
HOUSTON, JUNE 18, 2025 ― In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center...
MD Anderson and HealthEx announce collaboration to develop new platform to give patients direct control of data access
The University of Texas MD Anderson Cancer Center and HealthEx today announced a strategic collaboration aimed at developing tools for...
Mailed self-collection HPV tests boost cervical cancer screening rates
Real-world study found self-collection tests were effective at increasing cervical cancer screening participation in underserved U.S. populations...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes, lymph nodes.
First-in-class antibody-drug conjugate, pivekimab sunirine (PVEK), was safe and effective.
PVEK achieved an overall response rate of 85% and complete response rate of 70% as frontline treatment in newly diagnosed patients with BPDCN.
Findings suggest this treatment should be considered...
